motor phenotypes of HSPs. It also remains unclear whether pure HSPs can be linked to cell-autonomous processes or are non-cell autonomous, and indeed whether there are "protective" features in nonspinal targets of upper motoneurons that result in some sparing of neuronal function.
In summary, Beetz and colleagues have generated what promises to be a very useful mouse model of HSP. Future studies of these mice should uncover important features of the pathogenic mechanisms underlying this disease. These mice will also be useful in developing a deeper understanding of ER membrane biology. It is likely that we will "REEP" the benefit of this work for some years to come. 
Differing phenotypes
There is a lack of consensus on the effect of Slc30a8 deletion on insulin secretion and circulation in mice (Table 1) . In all reports, the consequence of Slc30a8 deletion appears to be relatively small. Studies using different mouse colonies with whole-body Slc30a8 deletion all agreed that Slc30a8 deletion does not affect glucose homeostasis in mice fed a normal chow diet. The studies disagreed on the role of Slc30a8 on proinsulin processing, glucose-stimulated insulin secretion (GSIS), and glucose tolerance. Nicolson et al. showed that while their male KO mice process proinsulin normally, they are glucose intolerant, secrete significantly less insulin during an intraperitoneal glucose tolerance test, and have increased fasting glucose levels (9). Interestingly, GSIS was significantly elevated in isolated islets. Conversely, Pound et al. found that their Slc30a8-KO mice have normal glucose tolerance, but significantly reduced fasting plasma insulin levels, along with a 33% reduction in GSIS (10, 11) . The Slc30a8-KO mice studied by Lemaire et al. lacked any significant phenotype when on normal chow (12) . Another study reported that β cell-specific deletion of Slc30a8 leads to decreased proinsulin processing, significantly reduced first-phase insulin secretion, and glucose intolerance during an oral glucose tolerance test (13) .
Interestingly, there are fewer phenotypic differences between colonies of mice subjected to prolonged high-fat diet (HFD) feeding. The studies agreed that Slc30a8-KO mice fed HFD display greater weight gain, fasting hyperglycemia, fasting hyperinsuhepatic insulin clearance in mice with pancreas perfusions and pancreas-liver perfusions while measuring insulin levels in the portal vein and the inferior vena cava. The difference between the two perfusions provided a measure of hepatic extraction. Their findings indicated that Slc30a8-KO mouse livers had enhanced single-pass insulin clearance (3) . A puff of Zn 2+ accompanies every burst of insulin secretion (7) . The authors hypothesized that Zn 2+ inhibits insulin secretion and hepatic insulin uptake, and, therefore, loss of the ZnT8 transporter should relieve the inhibition of insulin secretion while simultaneously increasing hepatic insulin uptake. In support of this hypothesis, direct Zn 2+ injection into the portal vein of mice or incubation with a hepatocyte cell line directly inhibited insulin uptake. In agreement with previous studies, deletion of Slc30a8 resulted in dramatic reduction of insulin crystals. Despite abnormal DCVs, more insulin was secreted, but was balanced by increased hepatic clearance. Conversely, studies in isolated islets and perfused pancreas showed that Zn 2+ inhibits insulin secretion (3) .
It has been proposed that β cell-derived Zn 2+ acts on α cells to suppress the glucagon secretion that accompanies insulin secretion. However, Tamaki et al. did not observe any difference in glucagon secretion in the Slc30a8-KO mice. Together with prior studies (8) , these data suggest that the Zn 2+ cosecreted with insulin is not responsible for the suppressive effect of insulin secretion on glucagon secretion.
(5), and a W325R SLC30A8 polymorphism is associated with T2D (6). Slc30a8 deletion in mice decreases DCV Zn 2+ content (4, (7) (8) (9) . A role for decreased Zn 2+ in DCV functional defects is not obvious, because some species (e.g., guinea pig) produce insulin molecules that do not bind to Zn 2+ but still maintain normal insulin secretion.
Tamaki et al. address contradictory findings concerning the effect of Slc30a8 deletion on insulin secretion in mice (3). Using β cell-specific deletion of Slc30a8, they report an insulin hypersecretion phenotype and suggest that functional ZnT8 facilitates autocrine and paracrine roles for the Zn 2+ burst produced by β cells upon glucose stimulation. In the WT animals, the released Zn 2+ bolus inhibited further insulin release, while loss of Slc30a8 resulted in sustained insulin secretion. Intriguingly, despite increased insulin secretion, peripheral insulin levels were lower and the C-peptide/insulin ratio was increased in KO mice. These data indicate that lower insulin levels might be due to increased insulin clearance from the bloodstream. Studies of proinsulin/insulin ratio and rates of insulin clearance in humans with the SLC30A8 W325R polymorphism were also consistent with this idea.
Zinc inhibition of hepatic insulin uptake
Quantitatively, the liver and the kidneys are the most important sites of insulin uptake and degradation. The liver is the first organ exposed to newly secreted insulin and can clear much of this insulin in a single pass. The authors investigated and glutamate residues directly adjacent to the insulin-docking site (Figure 1) . One of these, H710, was recently shown to be critical in the interaction with insulin (16) . We note that this histidine residue is within hydrogen bonding distance to E706, both of which are in the carboxyterminal α chain (αCT) helix of the insulin-binding pocket. With minimal conformational changes, these residues, along with E97 and/or D707 or a water molecule, could form a tetrahedral coordination environment favored for Zn 2+ binding (Figure 1 ). This raises the possibility that Zn 2+ influences insulin clearance in part through direct competition with insulin for IR binding. Intriguingly, insulin monomers contain a potential Zn 2+ binding site. H10 of the insulin molecule is critical for Zn 2+ binding the hexameric form, but is absent in insulin variants that do not bind to Zn 2+ (17) . The adjacent E13 is in proximity to coordinate to the same Zn 2+ ion. It is unknown whether Zn 2+ occupancy at these putative sites inhibits or perhaps stabilizes the IR-insulin interaction, as is the case for other hormone-receptor interactions (1). Additional features of Zn 2+ -histidine coordination chemistry are relevant to insulin biology. The histidine-rich domain of ZnT8 is essential for Zn 2+ binding. Through binding to two critical histidine residues, Zn 2+ activates the K ATP channel and hyperpolarizes β cells, which leads to inhibition of insulin secretion (18) . This potentially explains how reduced Zn 2+ uptake by β cells could promote increased insulin secretion.
Future directions
Answering the questions evoked by these findings will require interdisciplinary teams that can pair physical and imaging methods with receptor physiology in model systems. Can Zn 2+ simultaneously bind histidine and glutamate side chains in the IR and insulin to stabilize the complex and/or to prevent internalization? Are the relative Zn 2+ affinities of the receptor, hormone, and heterodimeric complex compatible with the transient concentration gradient produced by pulsed Zn 2+ release into the portal vein? Does Zn 2+ only block insulin internalization, or does it also block insulin signaling? Answers to this question might help distinguish binding and signaling events. Are there other receptors that bind Zn 2+ and are affected by the insulin secretion-dependent Zn 2+ burst? How much Zn 2+ escapes hepatic clearance and albumin binding to exert actions on extrahepatic tissues? tleneck when challenged by the increased demand posed by insulin resistance.
How might Zn 2+ influence hepatic extraction of insulin? Tamaki et al. showed that Zn 2+ levels did not affect the activity of the insulin-degrading enzyme. This observation is consistent with the effect of Zn 2+ being restricted to insulin internalization. Blockade of insulin internalization was enhanced by pyrithione, a Zn 2+ ionophore. This suggests that internalized Zn 2+ is responsible for the inhibitory effect; however, the effect was independent of the Zn 2+ transporter ZIP-14.
Tamaki et al. make the case that pulsatile release of Zn 2+ inhibits clathrin-dependent insulin endocytosis via a complex with the insulin receptor (IR). Two physiochemical features of Zn 2+ binding to proteins may provide an additional and direct antagonistic effect on IR-insulin interaction. First, Zn 2+ is known to stabilize the hexameric form of insulin in plasma, which may not bind as tightly to the IR. Second, Zn 2+ may be a competitive inhibitor at the insulin-binding site of IR, acting as an antagonist of insulin binding and/or internalization. In many Zn 2+ -dependent proteins, Zn 2+ forms between three and five tight coordinate covalent bonds to side chains such as His, Glu, Asp, and Cys. Inspection of a recent IR structure (16) revealed a cluster of Zn 2+ -binding histidine linemia, and glucose intolerance (9, 12, 14) . The role of Slc30a8 deletion on insulin sensitivity is still debated. Nicolson et al. (9) and Hardy et al. (14) reported decreased insulin sensitivity in their Slc30a8-KO colonies after prolonged HFD feeding; however, Lemaire et al. found insulin sensitivity to be unchanged (12) .
Differences in genetic background may explain phenotypic differences. Pound et al. found that Slc30a8 deletion in two genetic backgrounds renders different phenotypes. They also reported sex-specific effects on resulting Slc30a8 deletion phenotypes (10) . Finally, Slc30a8 deletion in mouse α cells did not produce a visible phenotype (13) .
Linking insulin, zinc, and the liver Deletion of PCSK1, a proprotein convertase that processes proinsulin, also blocks mature insulin formation and produces β cell DCVs that are essentially devoid of aggregated insulin. The mice have hyperproinsulinemia, but apparently normal glucose tolerance (15) . Thus, disruption of DCV maturation does not always lead to impaired regulated secretion. Like SLC30A8, PCSK1 has emerged as a genetic factor of T2D. Deficiency of these genes appears tolerable in animals with a normal demand for insulin secretion, but might produce a bot-
Figure 1
Putative Zn 2+ -binding residues at the IR-insulin interface. Model of a putative Zn 2+ -binding site in the insulin-binding site of the IR. The protein coordinates are from the IR-insulin crystal structure (PDB-ID 3W11). Insulin -chains InsA (gold) and InsB (black) are shown -engages with the IR at the αCT (purple). The IR core particle β strands are also shown (light cyan). A Zn 2+ ion (transparent sphere) has been modeled in the structure based on the environment and known Zn 2+ -coordinating abilities of the highlighted residues. IR residues (green sticks) H710 and E706 (from the αCT) and E97 form a putative Zn 2+ -binding site. A water molecule or InsB side chains can complete the tetracoordinated Zn 2+ site after helix rotation/displacement (not shown). Intriguingly, E706 forms a H-bond to a backbone amide on InsB: this docking of the hormone with its receptor could be disrupted by binding of the zinc ion.
Although fasting insulin is used as a surrogate measure of insulin resistance, it has a stronger correlation with insulin clearance, which is highly heritable (19, 20) . Future human genetic studies will be important for determining whether genetic variation in SLC30A8 contributes to T2D entirely through its effect on insulin clearance and how much of the heritability of insulin clearance is due to SLC30A8.
These studies illustrate how in-depth phenotyping, which requires model organisms, can take clues from human genetics and provide mechanistic explanations for relationships between genetic variation and human disease. Results from these studies can now be used to study subphenotypes associated with diabetes susceptibility. In this case, it may motivate study of the relationship among inorganic physiology (such as the Zn 2+ fluxes described here), genetic variation at the SLC30A8 locus, and insulin clearance. Most importantly, these deeper phenotypes should be present in nondiabetics, and thus can be studied independently of the disease. 
